2025
Sleep and Circadian-Related Outcomes after Critical Illness
Pisani M. Sleep and Circadian-Related Outcomes after Critical Illness. Seminars In Respiratory And Critical Care Medicine 2025 PMID: 40164118, DOI: 10.1055/a-2531-1137.Peer-Reviewed Original ResearchPost-intensive care syndromeCircadian disruptionExamined symptomsConstellation of symptomsSleep complaintsInfluence long-term outcomesSurvivors of critical illnessIntensive care unitIntensive care unit environmentSleepCritical illnessQuality of lifeCritically ill patientsIll patientsIllnessPost-ICUSymptomsStudy of critically ill patients
2024
Long-term outcomes after treatment of delirium during critical illness with antipsychotics (MIND-USA): a randomised, placebo-controlled, phase 3 trial
Mart M, Boehm L, Kiehl A, Gong M, Malhotra A, Owens R, Khan B, Pisani M, Schmidt G, Hite R, Exline M, Carson S, Hough C, Rock P, Douglas I, Feinstein D, Hyzy R, Schweickert W, Bowton D, Masica A, Orun O, Raman R, Pun B, Strength C, Rolfsen M, Pandharipande P, Brummel N, Hughes C, Patel M, Stollings J, Ely E, Jackson J, Girard T. Long-term outcomes after treatment of delirium during critical illness with antipsychotics (MIND-USA): a randomised, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine 2024, 12: 599-607. PMID: 38701817, PMCID: PMC11296889, DOI: 10.1016/s2213-2600(24)00077-8.Peer-Reviewed Original ResearchEffects of antipsychotic treatmentCognitive impairmentAssociated with long-term cognitive impairmentTreat deliriumLong-term cognitive impairmentLong-term outcomesTreatment of deliriumCritically ill patientsAntipsychotic treatmentZiprasidone groupHaloperidol groupFollow-upQuality-of-life outcomesAssessed survivorsZiprasidoneHaloperidolAntipsychoticsCognitive outcomesTreatment group assignmentDepartment of Veterans AffairsQuality-of-lifeIll patientsPlacebo-controlledCritical illnessLong-term follow-up
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply